This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on earnings and revenues when it releases second-quarter 2021 results.
ILMNNegative Net Change SRPTNegative Net Change SRNENegative Net Change
biotechs
Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021. Resultantly, the stock rises.
BMRNPositive Net Change RGENPositive Net Change ARVNNegative Net Change BCYCNo Net Change
biotechs
Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.
NVSPositive Net Change IRWDNegative Net Change INCYPositive Net Change ABBVPositive Net Change
biotechs earnings
Company News for Jul 28, 2021
by Zacks Equity Research
Companies In The News Are: RGEN, SIRI, BSX, FISV.
BSXPositive Net Change FISVPositive Net Change SIRIPositive Net Change RGENPositive Net Change
biotechs business-services consumer-discretionary medical
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
by Zacks Equity Research
On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.
AVXLNegative Net Change CTMXNegative Net Change CRVSNegative Net Change EVLONo Net Change
biotechs
Gilead (GILD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.
IRWDNegative Net Change PFENegative Net Change GILDPositive Net Change ABBVPositive Net Change
biotechs earnings
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY
by Zacks Equity Research
Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.
GSKPositive Net Change NVSPositive Net Change BIIBPositive Net Change BMYNegative Net Change JNJPositive Net Change PFENegative Net Change BMRNPositive Net Change TLRYNegative Net Change
biotechs pharmaceuticals
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.
IRWDNegative Net Change BMYNegative Net Change PFENegative Net Change
biotechs earnings pharmaceuticals
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and pipeline progress.
VRTXNegative Net Change ILMNNegative Net Change SRPTNegative Net Change
biotechs
Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy
by Zacks Equity Research
Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas. The stock rises 9% post the announcement.
PFENegative Net Change BMRNPositive Net Change ARVNNegative Net Change
biotechs
Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.
BIIBPositive Net Change RHHBYNegative Net Change JNJPositive Net Change MRKPositive Net Change
biotechs
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
by Zacks Equity Research
Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.
BMRNPositive Net Change EXASPositive Net Change ALBOPositive Net Change TVTXNegative Net Change
biotechs
Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX
by Zacks Equity Research
The biotech sector was in focus last week on updates form Regeneron (REGN) and Bristol Myers (BMY).
REGNNegative Net Change BMYNegative Net Change BMRNPositive Net Change VRTXNegative Net Change
biotechs
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan
by Zacks Equity Research
Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.
REGNNegative Net Change GSKPositive Net Change RHHBYNegative Net Change VIRNegative Net Change
biotechs
Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe
by Zacks Equity Research
Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.
CDXSNo Net Change ATNXPositive Net Change BCYCNo Net Change ARQTNegative Net Change
biotechs
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval
by Zacks Equity Research
Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.
CDXSNo Net Change ALBOPositive Net Change BCYCNo Net Change ARQTNegative Net Change
biotechs
Vertex (VRTX) Initiates Phase II Study on Pain Candidate
by Zacks Equity Research
Vertex (VRTX) starts phase II study for VX-548 to treat acute pain after bunionectomy surgery & expects to start another phase II study to treat acute pain after abdominoplasty surgery in a few weeks.
BMRNPositive Net Change VRTXNegative Net Change AGENPositive Net Change
biotechs
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.
NVSPositive Net Change BIIBPositive Net Change RHHBYNegative Net Change PFENegative Net Change
biotechs
Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.
RHHBYNegative Net Change BMYNegative Net Change MRKPositive Net Change RGENPositive Net Change
biotechs
Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA
by Zacks Equity Research
The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.
LLYPositive Net Change BAYRYPositive Net Change INCYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Bear of the Day: Vericel (VCEL)
by Kevin Cook
Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside
VCELPositive Net Change UNHNegative Net Change MDWDNegative Net Change
biotechs genetics medical
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study
by Zacks Equity Research
Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.
AZNNegative Net Change ALXNPositive Net Change RGENPositive Net Change ZTSPositive Net Change
biotechs medical pharmaceuticals
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
by Zacks Equity Research
Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.
BMRNPositive Net Change EXASPositive Net Change ACADPositive Net Change SYBXPositive Net Change
biotechs
Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study
by Zacks Equity Research
Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.
GSKPositive Net Change RGENPositive Net Change TECHPositive Net Change VIRNegative Net Change
biotechs
BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
RHHBYNegative Net Change PFENegative Net Change BMRNPositive Net Change SGMOPositive Net Change
biotechs